B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biocryst Pharma Inc (NQ: BCRX )

10.58 -0.20 (-1.86%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,780,525
Open 10.80
Bid (Size) 10.56 (10)
Ask (Size) 10.70 (1)
Prev. Close 10.78
Today's Range 10.56 - 10.98
52wk Range 7.610 - 19.99
Shares Outstanding 185,583,896
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash. 
Via Benzinga
BioCryst Pharmaceuticals Stock Is Tumbling: What's Going On?
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares are trading lower Monday after the company announced preliminary fourth-quarter and full 
Via Benzinga

Performance

YTD
-7.60%
-7.60%
1 Month
-5.28%
-5.28%
3 Month
-20.75%
-20.75%
6 Month
-2.40%
-2.40%
1 Year
-28.85%
-28.85%

More News

Read More
TSLA Stock Price Prediction: What to Know as Analysts Slash Tesla Price Targets
Via InvestorPlace
BioCryst Shelves Development Of Rare Blood Disorder Candidate
Via Benzinga
Expert Ratings for BioCryst Pharmaceuticals
Via Benzinga
Why Is Getaround (GETR) Stock Up 6% Today?
Via InvestorPlace
BCRX Stock Sinks as BioCryst Discontinues Drug Development
Via InvestorPlace
Novavax, Tesla, Western Digital And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
Via Benzinga
VF Corp, Verve Therapeutics And Some Other Big Stocks Moving Lower On Monday
Via Benzinga
BioCryst Pharmaceuticals Stock Sees RS Rating Rise To 84
Via Investor's Business Daily
BioCryst Pharmaceuticals (BCRX) Q3 2022 Earnings Call Transcript
Via The Motley Fool
4 Analysts Have This to Say About BioCryst Pharmaceuticals
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022
Via Benzinga
Goodyear Tire, Catalent, Zebra Technologies And Some Other Big Stocks Moving Lower On Tuesday
Via Benzinga
Why Harsco Shares Surged Over 22%; Here Are 80 Biggest Movers From Yesterday
Via Benzinga
Why Abiomed Shares Are Trading Higher By Over 50%? Here Are 60 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
What's Going On With BioCryst Pharmaceuticals Stock Today?
Via Benzinga
BioCryst Pharmaceuticals: Q3 Earnings Insights
Via Benzinga
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
Via Investor's Business Daily
BioCryst Pharmaceuticals Stock Shows Rising Relative Strength
Via Investor's Business Daily
Kalvista Crashes Nearly 60% After Adding HAE Drug To The Scrap Heap
Via Investor's Business Daily
3 Biotech Stocks to Buy Now for Extraordinary Gains
Via InvestorPlace
BioCryst Secures FDA Orphan Drug Status For Rare Connective Tissue Disease Candidate
Via Benzinga
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
BioCryst Exhibits Positive Data From Early-Stage Rare Kidney Disease Study
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.